Bayer’s Diane-35 (cyproterone
acetate/ethinylestradiol) will be
reintroduced to the French market.
Withdrawn after a suspension
on 21 May 2013, the European
Medicines Agency (EMA) conducted
a review of the benefit-risk profile
and concluded the benefits
outweighed the risks, Bayer said.
The suspension had followed
French regulator ANSM’s statement
that 4 deaths due to thrombosis
were linked to the drug’s use over
25 years Reuters reported.
Bayer said it had been liasing
with the TGA in Australia about the
drug and had advised them of the
positive outcome in Europe.The above article was sent to subscribers in Pharmacy Daily's issue from 17 Jan 14 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 17 Jan 14
MONTU Group, its subsidiary Alternaleaf Pty Ltd, and their common director Christopher Strauch are facing legal action by the Therapeutic Goods Administration (TGA) in the Federal Court of Australia for alleged unlawful advertising on the effectiveness of their medicinal cannabis products.
AUSTRALIA’S public hospitals are facing their lengthiest wait times on record for planned surgeries, with emergency departments struggling under access blockages, according to the latest annual Public Hospital Report Card by the Australian Medical Association (AMA).
THE University of South Australia has released a new study to help healthcare workers better support women with persistent pelvic pain, including symptoms that are suggestive of gynaecological, lower urinary tract, bowel, sexual, and pelvic floor dysfunction.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.